home  about  experts  links
MPT WWW
 

Category: Conflict of Interest Regulation

   Over the last several decades the increased pace of medical and pharmaceutical innovation has led physicians, hospitals, and academic centers to search for new sources of funding for projects in an effort to improve patient care. This has led to greater interaction between physicians, industry representatives, and physicians who work or consult for the health care industry in the development of new products and services. Many critics, however, are suspicious of the relationships between industry and physicians and have called for quarantining medical practice from the supposedly baleful influence of market incentives under the rubric of stronger conflict of interest regulation.

   Despite the noble intentions of proponents, using ever more restrictive conflict of interest regulations to police the marketplace for medical information is not only short-sighted, but counterproductive. By limiting doctors' access to information on or participation in the development of new treatment and prevention alternatives, the conflict of interest movement ultimately reduces patients' access to care.

   Each one of the health care stakeholders-physicians, insurers, industry, government-has a bias (or perspective, if you will) that affects how they process and present information to the public. The challenge is not to purify the public square of provincial interests (an impossible task), but to structure our deliberations so that each of the participants carefully monitors the activities of the other in a fashion aligned with the ultimate goal of health policy: improving patient health and well-being.

[Spotlight] [Commentary] [Research] [Events] [News]


Spotlight


Commentary


Research


News

MPT on Twitter
MPT on Facebook

Conflict of Interest Regulation

Consumer Driven Health Care

Drug & Medical Device Innovation

Drug & Medical Device Litigation

FDA Regulation

Global Health

Health Care Policy

Intellectual Property
Rights & Innovation

Medicare and Medicaid

Personalized Medicine

Value of Medicine


NEW SECOND OPINION!
Experts Discuss Foreign Clinical Drug Trials in Our "Second Opinion" Expert Forum!

Expert Panel:
  • David Henderson
  • Anup Malani
  • Henry Miller
  • Tomas J. Philipson
  • Tevi Troy

Click here to read their second opinions.

Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org